Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 25mcg Clear all
Completed Phase 3 Interventional Results available

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02152605
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • Upland, California • Clearwater, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of VisionPure™ on Indices of Vision Health and Cognitive Function

NCT05533658
View directory record Official record
Conditions
Eye Health, Vision, Cognitive Function
Interventions
VisionPure Dietary Supplement, Placebo
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Lutz, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Not applicable Interventional

Misoprostol With Mechanical Dilation Versus Oxytocin With Mechanical Dilation for High-risk Pregnancy Inductions

NCT04492072
View directory record Official record
Conditions
Cesarean Section, Misoprostol, Oxytocin, High Risk Pregnancy
Interventions
Oxytocin, Misoprostol
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 19, 2026, 2:55 AM EDT
Terminated Phase 4 Interventional Results available

Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention

NCT03476369
View directory record Official record
Conditions
Percutaneous Coronary Intervention
Interventions
Fentanyl, Ticagrelor 90Mg Tablet
Drug
Lead sponsor
The Guthrie Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Sayre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment

NCT00519792
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Omega DUROS device
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00676052
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK233705 12.5mcg, GSK233705 25mcg, GSK233705 50mcg, GSK233705 100mcg, GSK233705 200mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
25
States / cities
Jasper, Alabama • Glendale, Arizona • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00606684
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GW642444 6.25, GW642444 3mcg, GW642444 12.5mcg, GW642444 25mcg, GW642444 50mcg, placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
49
States / cities
Florence, Alabama • Jasper, Alabama • Montgomery, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 4 Interventional

Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients

NCT03611699
View directory record Official record
Conditions
COPD
Interventions
Umeclidinium / Vilanterol Dry Powder Inhaler, Placebo
Drug
Lead sponsor
Gary L. Pierce
Other
Eligibility
30 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 19, 2026, 2:55 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Analgesic Techniques on Duration of Spontaneously Laboring Patients

NCT01982838
View directory record Official record
Conditions
Effects of; Anesthesia, in Labor and Delivery, Pregnancy, Prolonged First Stage of Labor
Interventions
Epidural de novo, CSE
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor

NCT02566005
View directory record Official record
Conditions
Pregnancy
Interventions
misoprostol, Foley bulb
Device
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

NCT02119286
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF, VI, UMEC, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

NCT02858310
View directory record Official record
Conditions
Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions
E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cervical Ripening in Premature Rupture of Membranes

NCT02314728
View directory record Official record
Conditions
Pregnancy, Premature Rupture of Membranes, Preterm Premature Rupture of Membranes, Unfavorable Cervix
Interventions
Misoprostol, Oxytocin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
15 Years to 50 Years · Female only
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01957163
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF, VI, UMEC, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Jasper, Alabama • Clearwater, Florida • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 19, 2026, 2:55 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Labor Protocol Study

NCT04004845
View directory record Official record
Conditions
Vaginal Delivery, Labor, Induced; Birth
Interventions
Cytotec, oxytocin, Cervical Foley Balloon
Drug · Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01323621
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Double-dummy placebo, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

NCT01323660
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719 125, GSK573719 62.5, GW642444 25, placebo
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older · Male only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Jasper, Alabama • Torrance, California • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 4 Interventional Results available

Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD

NCT04606394
View directory record Official record
Conditions
COPD
Interventions
Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Ventolin 90Mcg/Actuation Inhalation Aerosol
Drug
Lead sponsor
Pulmonary Research Institute of Southeast Michigan
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy

NCT03115515
View directory record Official record
Conditions
Pregnancy Related, Thyroid
Interventions
levothyroxine
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

NCT01313676
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate/vilanterol, fluticasone furoate, vilanterol, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
16,568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
506
States / cities
Andalusia, Alabama • Athens, Alabama • Birmingham, Alabama + 369 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

NCT01328444
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK 573719 +GW642444 125/25, GSK573719 + GW642444 62.5/25, GSK 573719 125, GSK 573719 62.5, GW642444 25, Plb
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Phoenix, Arizona • Lebanon, New Hampshire • Albany, New York + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 19, 2026, 2:55 AM EDT
Recruiting Not applicable Interventional

A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients

NCT03977207
View directory record Official record
Conditions
Thyroid; Functional Disturbance, Hypothyroidism, Hemodialysis
Interventions
Levothyroxine Sodium, Placebos
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma

NCT00441441
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate, fluticasone propionate/salmeterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Huntington Beach, California • Long Beach, California • Riverside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 19, 2026, 2:55 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01017952
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
89
States / cities
Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 19, 2026, 2:55 AM EDT